HUTCHMED (China) Ltd
H7T1
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,796
Stocks News & Analysis
stocks
Why Morningstar thinks Anthropic is worth $1.7 trillion
A look at how we arrive at our base-case valuation for the AI lab, along with bull and bear scenarios.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,267.80 | 104.40 | 1.14% |
| CAC 40 | 8,278.59 | 45.30 | 0.55% |
| DAX 40 | 26,347.45 | 80.26 | 0.31% |
| Dow JONES (US) | 52,146.04 | 243.71 | -0.47% |
| FTSE 100 | 10,751.59 | 31.28 | -0.29% |
| HKSE | 24,557.04 | 108.09 | 0.44% |
| NASDAQ | 24,953.43 | 299.71 | -1.19% |
| Nikkei 225 | 60,459.58 | 1,684.08 | 2.87% |
| NZX 50 Index | 14,167.41 | 193.79 | 1.39% |
| S&P 500 | 7,499.36 | 50.58 | -0.67% |
| S&P/ASX 200 | 9,129.00 | 99.30 | 1.10% |
| SSE Composite Index | 3,663.72 | 2.93 | 0.08% |